EP4009997A1 - Extrakt von silybum marianum (l.) gaertn. akenes zur förderung des haarwuchses - Google Patents

Extrakt von silybum marianum (l.) gaertn. akenes zur förderung des haarwuchses

Info

Publication number
EP4009997A1
EP4009997A1 EP20754703.5A EP20754703A EP4009997A1 EP 4009997 A1 EP4009997 A1 EP 4009997A1 EP 20754703 A EP20754703 A EP 20754703A EP 4009997 A1 EP4009997 A1 EP 4009997A1
Authority
EP
European Patent Office
Prior art keywords
weight
extract
alopecia
achenes
gaertn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20754703.5A
Other languages
English (en)
French (fr)
Inventor
Jean-Hilaire Saurat
Daniel BACQUEVILLE
Hélène DUPLAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Dermo Cosmetique SA
Original Assignee
Pierre Fabre Dermo Cosmetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Dermo Cosmetique SA filed Critical Pierre Fabre Dermo Cosmetique SA
Publication of EP4009997A1 publication Critical patent/EP4009997A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to an extract of achenes from Silybum marianum (L.) Gaertn., As well as to compositions containing this extract for application in the fields of cosmetics and dermatology for promoting hair growth. STATE OF THE ART
  • Hair care not only for cosmetic purposes but also to prevent hair loss and to regenerate it, has always required the spirit of research.
  • Many theories have attempted to shed light on the aetiology of hair loss in cases of baldness, alopecia, alopecia areata, etc., blaming them on an increase in the tension of the tissue on the sphere. cranial, reduced blood supply, or certain endocrine or nervous disorders.
  • the hair follicle is a mini-organ anchored in the skin up to the hypodermis, whose main function is the production of a hair shaft.
  • the distribution of hair follicles is established during growth in utero and their number is determined genetically.
  • the hair follicle is a dynamic structure that produces hair during the cycle of tissue growth and remodeling. This cycle is broken down into three phases:
  • a growth phase (anagen), the cells of the dermal papilla (fibroblasts) send a signal to the stem cells of the bulb which allows their proliferation.
  • Cells will transform and envelop the dermal papilla to form the hair's sulfur matrix. They divide and differentiate into follicular keratinocytes, cells responsible for the structure of the hair. For the hair to be well structured, these keratinocytes need sulfur proteins, vitamin B6 and various minerals such as zinc and magnesium.
  • the duration of this phase determines the length of the hair and depends on the proliferation and differentiation of the cells of the matrix at the base of the follicle.
  • a phase of regression (catagen)
  • the matrix dies and therefore the papilla skin is no longer in contact with this matrix.
  • the follicle and the dermal papilla ascend towards the epidermis.
  • telogen the cells of the dermal papilla and bulb are intact and inactive. The hair falls out. For a new hair to grow, the cycle must be restarted.
  • the hair is therefore constantly renewed and of the 100,000 to 150,000 hairs in a head of hair, the majority is in the growth phase. There is a normal and physiological loss of hair in the range of 60 to 100 per day for healthy hair. Beyond that, the fall is said to be pathological, whether it is occasional or installed.
  • alopecia refers to the partial or general lack of hair on the head. Effluvium is excessive hair loss.
  • alopecia Many factors can be involved in alopecia such as genetic factors, age, gender, illnesses, stress, hormonal problems, side effects of drugs, scarring. It is possible to distinguish several forms of alopecia:
  • Hereditary androgenetic alopecia is the most common; premature hair loss occurs in genetically predisposed subjects and particularly affects men. It is manifested by a decrease in hair volume, even baldness and affects 50% of men over 50 years old.
  • Postmenopausal alopecia is the most common cause of baldness in women. Hair loss is more diffuse and extensive in women than in men. Diffuse female alopecia is a disorder that often starts at menopause and affects about 40% of women over the age of 70. The term diffuse illustrates that, unlike men, hair loss affects the entire scalp, evenly.
  • Acute or reactive alopecia can be linked to drug treatment (including cancer treatments), stress, childbirth, severe dietary deficiencies, iron deficiency, hormonal disorders, it is a fall simultaneous and diffuse of a large amount of hair.
  • Scarring alopecia it can be caused by skin problems (tumor, burn, alopecia areata), acute irradiation, lupus erythematosus or parasites (ringworm, lichen).
  • Congenital alopecia rare, it corresponds to the absence of a root or to hair abnormalities (mutations).
  • alopecia also covers a whole family of damage to the hair follicle, the final consequences of which are permanent, partial or general loss of hair.
  • Diffuse hair loss common alopecia, telogen effluvium, anagen effluvium, alopecia areata. Among diffuse hair loss, the most frequent are common alopecia (male and female androgenetic alopecia) and G telogen effluvium (after high fever, pregnancy, medication or severe diet).
  • Localized hair loss androgenetic alopecia, alopecia areata, scarring alopecia, tumors. Localized hair loss is observed in the context of male androgenetic alopecia (gulfs, tonsure), alopecia areata, alopecia induced by traction (trichotillomania, braiding and straightening) or cicatricial alopecia (central cicatricial alopecia centrifugal, postmenopausal fibrosing frontal alopecia). Mention may also be made of inflammatory cicatricial alopecia, in particular folliculitis including dissecting folliculitis and decalvating folliculitis. Tumors and growths of the skin are also accompanied by localized hair loss (sebaceous hamartoma, basal cell carcinoma, squamous cell carcinoma).
  • Alopecia is essentially linked to a disturbance in hair renewal which initially results in the acceleration of the frequency of cycles at the expense of the quality of the hair and then of its quantity.
  • the most frequent phenomenon is a reduction in the duration of the growth phase (anagen phase) in connection with an arrest of cell proliferation.
  • the consequence is a premature induction of the catagen phase and a greater number of hair follicles in the telogen phase and therefore a greater loss of hair.
  • it is therefore necessary to restart the hair cycle, for example by activating the anagen phase.
  • vitamins such as vitamins A, E, B5, B6, C, H, and PP
  • trace elements such as zinc, copper, magnesium, silicon
  • protein derivatives such as peptides, sulfur-containing amino acids (methionine, cystine, cysteine or derivatives type); essential oils or extracts of plant origin of a lipophilic or hydrophilic nature, the list of which is not exhaustive
  • antifungal agents such as piroctone olamine, undecylenic derivatives, cyclopriroxolamine; synthetic chemical molecules known for their specific action on androgen receptors or on the activity of 5- ⁇ reductases.
  • Minoxidil or 2,4-diamino-6-piperidinopyrimidine 3-oxide is now the reference in the treatment of androgenetic alopecia. Despite the many theories raised about its mechanism of action, it is not clearly understood. In addition, its effectiveness remains limited, because even if a stabilization of hair loss is observed in many clinical cases, a resumption of the alopecia process is observed as soon as the treatment is stopped. Its restrictive daily use is probably the cause of undesirable side effects noted in patients using it long term, such as localized skin reactions or systemic effects.
  • compositions comprising very diverse active agents are proposed in hair regrowth, these active agents possibly being derivatives of 2,4-diaminopyrimidine 3-oxide such as those described in patent application EP0522964.
  • active agents possibly being derivatives of 2,4-diaminopyrimidine 3-oxide such as those described in patent application EP0522964.
  • Clinical studies have demonstrated that PGF2a analogues have the property of inducing the growth of hair and eyelashes in humans and animals (Johnstone, Am J Opht, 124 (4), 544-547, 1997).
  • a prostaglandin E2 analogue, viprostol has the property of increasing hair density.
  • Application WO98 / 33497 describes pharmaceutical compositions containing prostaglandins or prostaglandin derivatives intended to promote hair growth.
  • Silybum marianum (L.) Gaertn. designates a plant belonging to the Asteraceae family, annual or biennial, with a robust stem, which can reach more than one meter in height. Its large, shiny, alternate leaves without stipule are mottled white and edged with hard, pointed thorns. The flowers are grouped in terminal heads, often solitary. They are surrounded by large, thorny bracts with very sharp ends. The flowers, tubular, five-lobed, are purplish-purple in color. The fruits are shiny achenes, black or marbled with yellow, topped with a crest with denticulate bristles in a ring at their base. The vernacular name of this plant is Milk Thistle.
  • Achene (often mistakenly referred to as seed in the literature) of Silybum marianum (L.) Gaertn. and its preparations are traditionally used orally, in the symptomatic treatment of functional digestive disorders attributed to hepatic origin.
  • the main active ingredient in achene from Silybum marianum (L.) Gaertn. is silymarin, a mixture of several flavonolignans (mainly silybin, isosilybin, silychristin, and silydianin).
  • Achenes contain up to 3% by weight of silymarin. They also consist of oil (20-30% by weight), mucilages and proteins.
  • Silymarin has been the subject of numerous studies (in vitro, in vivo and clinical) which have demonstrated its antioxidant, hepatoprotective, digestive and anti-inflammatory properties.
  • Silybin (a major silymarin flavonoid) has also been the subject of a very recent study in hair growth (Cheon et al., J Microbiol Biotech 29 (2), 321-329, 2019) via the Akt Wnt / -catenine signaling.
  • Application WO2018 / 002338 describes an extract of achenes from Silybum marianum (L.) Gaertn. poor in silymarin which has interesting properties for the treatment of acne, seborrhea, rosacea or seborrheic dermatitis.
  • an extract of achenes from Silybum marianum (L.) Gaertn. poor in silymarin has pharmacological activities of interest in the field of treatment and / or prevention for combating hair loss, in particular by promoting their growth.
  • the inventors have demonstrated that an extract of achenes from Silybum marianum (L.) Gaertn. poor in silymarin induces an increase in the expression of the protein Keratin 75 in the follicles.
  • the extract of achenes from Silybum marianum (L.) Gaertn. poor in silymarin will help to delay and prevent hair loss and extend the hair's life cycle.
  • the invention relates to an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract for its use for promoting hair growth and in particular for treating or preventing alopecia such as alopecia androgenetic, reactive alopecia, postmenopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • alopecia such as alopecia androgenetic, reactive alopecia, postmenopausal alopecia or alopecia areata
  • cicatricial alopecia in particular folliculitis and preferably dissecting folliculitis.
  • the invention also relates to the use, in particular cosmetic or dermatological, of an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract to promote hair growth and in particular to treat or prevent alopecia such as androgenetic alopecia, reactive alopecia, postmenopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • alopecia such as androgenetic alopecia, reactive alopecia, postmenopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • the invention also relates to the use of an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract for the preparation of a cosmetic or dermatological composition intended to promote hair growth and in particular to treat or prevent alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • the invention also relates to a method, in particular cosmetic or dermatological, for promoting hair growth and in particular for treating or preventing alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis, comprising the administration to a person in need thereof of an effective amount of an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract.
  • alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata
  • cicatricial alopecia in particular folliculitis and preferably dissecting folliculitis
  • the present invention relates to a dermatological or cosmetic composition
  • a dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract, with at least one dermatologically or cosmetically acceptable excipient for its use for promoting hair growth and in particular for treating or preventing alopecia such as androgenetic alopecia, reactive alopecia, postmenopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • alopecia such as androgenetic alopecia, reactive alopecia, postmenopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • the invention also relates to the use, in particular cosmetic or dermatological, of a dermatological or cosmetic composition
  • a dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract, with at least one dermatologically or cosmetically acceptable excipient, to promote hair growth and in particular to treat or prevent alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis.
  • alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or else cicatricial alopecia, in particular folliculitis and preferably dissecting
  • the invention also relates to the use of a dermatological or cosmetic composition
  • a dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract, with at least one dermatologically or cosmetically acceptable excipient, for the preparation of a medicinal product intended for promote hair growth and in particular to treat or prevent alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or even cicatricial alopecia, in particular folliculitis and preferably dissecting folliculitis .
  • alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or even cicatricial alopecia, in particular folliculitis and preferably dissec
  • the invention also relates to a method, in particular cosmetic or dermatological, for promoting hair growth and in particular for treating or preventing alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or scarring alopecia, in particular folliculitis and preferably dissecting folliculitis, comprising the administration to a person in need thereof of an effective amount of a dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract, with at least one dermatologically or cosmetically acceptable excipient.
  • alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or scarring alopecia, in particular folliculitis and preferably dissecting
  • the present invention relates to a method of dermatological treatment of an area of the scalp devoid of hair, comprising the topical application to the area of the scalp devoid of hair of an extract of achenes from Silybum marianum ( L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract or of a dermatological composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn.
  • the plant Silybum marianum (L.) Gaertn. may be referred to for short by the term Silybum marianum.
  • silymarin is understood to mean a purified extract of achenes from Silybum marianum (L.) Gaertn. predominantly comprising (at least 95% by weight) a mixture of the following four flavonolignans: silybin, isosilybin, silychristin and silydianin (Kuki et al., Chromatographia 75: 175-180, 2012).
  • a silymarin content of less than 0.2% by weight therefore means that the total amount of the constituents of silymarin is less than 0.2% by weight.
  • Such a content can be determined in particular by HPLC (High Performance Liquid Chromatography) or UPLC (Ultra High Performance Liquid Chromatography) by calculating the total area of the peaks corresponding to all the constituents of silymarin, in particular by using a reference silymarin sample, which can be obtained for example from Sigma Aldrich, to determine the position of these peaks.
  • HPLC High Performance Liquid Chromatography
  • UPLC Ultra High Performance Liquid Chromatography
  • sibin also called silibinin in the art, is meant, within the meaning of the present invention, the four diastereoisomers silybin A, silybin B, 2,3-cis-silybin A and 2,3-cis-silybin B.
  • isosilybin is meant, within the meaning of the present invention, the two diastereoisomers isosilybin A and isosilybin B.
  • silychristin is meant, within the meaning of the present invention, the two diastereoisomers silychristin A and silychristin B.
  • approximately is meant in the present description that the value concerned may be less than or greater than 10%, in particular of 5%, in particular 2%, more particularly 1%, to the indicated value.
  • dry extract is meant, within the meaning of the present invention, an extract devoid of extraction solvent or support, or containing only in the state of insignificant trace. Such a dry extract thus contains only material derived from Silybum marianum (L.) Gaertn. It may also contain insignificant traces of extraction solvent.
  • organic solvent immiscible with oil obtained from achenes of Silybum marianum (L.) Gaertn. Is meant, within the meaning of the present invention, an organic solvent which is not capable of mixing, or only partially, with the oil obtained from achenes of Silybum marianum (L.) Gaertn., So that the mixture of the organic solvent and of the oil obtained from achenes of Silybum marianum (L.) Gaertn. gives a heterogeneous mixture in which at least two distinct phases can be observed.
  • free fatty acid is meant, within the meaning of the present invention, a fatty acid not bound to other molecules (for example to glycerol or derivatives thereof to give glycerides or an alcohol to give a fatty ester).
  • tocopherol means Ga-tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and d-tocopherol.
  • C1 to C3 alcohol is understood to mean an R2 — OH alcohol whose R2 chain is a saturated, linear or branched hydrocarbon chain comprising 1 to 3 carbon atoms. It may be methanol, ethanol, // - propanol or isopropanol, in particular methanol, ethanol or isopropanol. Preferably, it will be ethanol or isopropanol, in particular ethanol.
  • room temperature is meant, within the meaning of the present invention, a temperature of 15 to 40 ° C, preferably 20 to 30 ° C, in particular of around 25 ° C.
  • hair and body hair is understood to mean the hair, the body hair, the eyebrows, the eyelashes and / or the coat, preferably the hair.
  • hair growth is understood to mean the growth of the hair and / or the hairs as defined above, preferably the hair.
  • alopecia is meant the total or partial loss of hair and / or body hair, for example linked to reduction in hair growth and / or acceleration of hair loss and / or body hair.
  • This term includes but is not limited to androgenetic alopecia, postmenopausal alopecia, reactive alopecia, cicatricial alopecia, alopecia areata, and congenital alopecia.
  • it will be androgenetic alopecia, postmenopausal alopecia, reactive alopecia or alopecia areata.
  • the consequences of alopecia are a temporary or permanent and partial or total absence of hair and / or body hair.
  • alopecia areata is meant a massive loss of hair by patches, most often in the scalp. Affected people have a plaque without hair, most often round or oval in shape. However, the scalp is not affected and does not present any scars.
  • area of the scalp devoid of hair is meant an area of the scalp, regardless of its size, which does not contain hair, or in which no longer grows enough hair to cover the area in question. It may be a patch of alopecia areata or partial or total alopecia.
  • folliculitis is meant an inflammation of one or more hair follicles, forming a papulo-pustule. It can therefore occur in all places with hair. Its origin can be bacterial, mycotic, viral or non-infectious. Folliculitis can be superficial, ostio-folliculitis, or deep. There are different scalp folliculitis, such as dissecting folliculitis or decalvating folliculitis.
  • Scalp dissecting folliculitis is a chronic and rare suppurative dermatosis of the scalp. It manifests as numerous painful follicular and perifollicular inflammatory nodules, pustules and abscesses that interconnect via sinus tracts, ultimately resulting in scarring alopecia.
  • Quinquaud's folliculitis is also an inflammatory cicatricial alopecia of the scalp, chronic and rare, occurring in middle-aged adults and characterized by the development of slowly extending and centrifugal alopecic plaques especially at the top and in the occipital area of the scalp. scalp, associated with perifollicular erythema, pustules and hemorrhagic crusts.
  • treating alopecia we mean stopping alopecia, reducing alopecia and / or improving alopecia.
  • “treating" alopecia includes limiting hair loss and / or body hair and / or promoting hair and / or body hair growth, increasing the density of hair follicles and / or regulating phases of the hair follicle cycle. .
  • preventing alopecia
  • reducing the risk of developing alopecia, or slowing the progression of alopecia in a mammal, preferably humans, which is susceptible to developing alopecia.
  • limit is understood to mean slowing down, reducing, reducing and / or stopping.
  • promote is meant to increase, increase, promote, enhance and / or accelerate.
  • cosmetic or dermatologically acceptable is intended to denote that which is useful in the preparation of a cosmetic or dermatological composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for a patient.
  • cosmetic or dermatological use in particular by topical application to the hair and / or scalp.
  • Topical application is meant an application to the skin, in particular to the scalp, mucous membranes, hair and / or body hair, in particular to hair and / or scalp. Extract according to invention
  • the extract according to the invention is an extract of achenes from Silybum marianum comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract.
  • the extract according to the invention contains at least 3% by weight, preferably at least 4% by weight of free linoleic acid relative to the weight of the dry extract.
  • the extract according to the invention contains between 3% and 25% by weight, for example between 3 and 20% by weight, in particular 3% and 15% by weight, in particular between 4% and 10% by weight, in in particular between 4% and 6% by weight, for example approximately 5% by weight of free linoleic acid relative to the weight of the dry extract.
  • the silymarin / free linoleic acid mass ratio of the extract according to the invention may in particular be less than 0.07, in particular less than 0.05 and in particular less than 0.01.
  • the extract according to the invention may also comprise between 10% and 70%, in particular between 10% and 50%, more particularly between 10% and 30% by weight, in particular between 15% and 25% by weight of acids free fat compared to the weight of the dry extract.
  • the extract according to the invention contains at least 0.01% by weight, in particular at least 0.05% by weight of tocopherols relative to the weight of the dry extract.
  • the extract according to the invention contains between 0.01% and 2% by weight, more particularly between 0.01% and 1% by weight, even more particularly between 0.01% and 0.5% by weight , in particular between 0.05% and 0.2% by weight, for example approximately 0.1% by weight of tocopherols relative to the weight of the dry extract.
  • the silymarin / tocopherols mass ratio of the extract according to the invention may in particular be less than 1, in particular less than 0.1.
  • the extract according to the invention contains between 3% and 25% by weight, for example between 3 and 20% by weight, in particular between 3% and 15% by weight, in particular between 4% and 10% by weight, in particular between 4% and 6% by weight, for example approximately 5% by weight of free linoleic acid relative to the weight of the dry extract; and between 0.01% and 2% by weight, in particular between 0.01% and 1% by weight, even more particularly between 0.01% and 0.5% by weight, especially between 0.05% and 0.2% by weight, for example approximately 0.1% by weight of tocopherols relative to the weight of the dry extract.
  • the silymarin / free linoleic acid mass ratio of the extract according to the invention may in particular be less than 0.07, in particular less than 0.01 and
  • the silymarin / tocopherols mass ratio of the extract according to the invention may in particular be less than 1, in particular less than 0.1.
  • the extract according to the present invention will be a dry extract.
  • the extract according to the invention can be obtained by a process according to the invention described below.
  • a process for preparing an extract according to the invention comprises in particular a step of extracting an oil obtained from achenes of Silybum marianum (L.) Gaertn. with an extraction solvent comprising, in particular consisting of, an aqueous hydrotropic solution, subcritical water or an organic solvent immiscible with oil obtained from achenes of Silybum marianum (L.) Gaertn. possibly mixed with water.
  • an extraction solvent comprising, in particular consisting of, an aqueous hydrotropic solution, subcritical water or an organic solvent immiscible with oil obtained from achenes of Silybum marianum (L.) Gaertn. possibly mixed with water.
  • the extraction solvent comprises, in particular consists of, an organic solvent immiscible with oil obtained from achenes of Silybum marianum (L.) Gaertn. possibly mixed with water.
  • the oil-immiscible organic solvent derived from achenes of Silybum marianum (L.) Gaertn. may in particular be a C 1 to C 3 alcohol .
  • the extraction solvent may in particular be a C 1 to C 3 alcohol optionally mixed with water.
  • the organic solvent immiscible with the oil obtained from achenes of Silybum marianum (L.) Gaertn. in particular a C 1 to C 3 alcohol such as methanol, ethanol or isopropanol, in particular ethanol or isopropanol, preferably ethanol, can be used as a mixture with water, in particular in an organic solvent / water volume ratio of 70/30 to 100/0, in particular from 80/20 to 100/0, for example example about 80/20 or 90/10.
  • the extraction solvent may in particular be chosen from methanol, a methanol / water mixture, ethanol, an ethanol / water mixture, isopropanol and an isopropanol / water mixture, in particular an ethanol / water mixture or an isopropanol / water mixture.
  • the extraction solvent will be methanol, an ethanol / water mixture in a volume ratio of approximately 80/20 or 90/10 or an isopropanol / water mixture in a volume ratio of approximately 90 / 10.
  • the step of extracting achenes from Silybum marianum oil will be carried out in particular by mixing the oil obtained from achenes from Silybum marianum with the extraction solvent for 1 to 12 h and in particular at a temperature between 15 and 25 ° C, especially around 20 ° C.
  • the amount of extraction solvent used to perform this extraction will advantageously be from 0.5 to 3 g, in particular from 1 to 3 g per 1 g of oil obtained from achenes of Silybum marianum (L.) Gaertn ..
  • the extraction phase will advantageously be separated from the lipid phase and recovered before being dried (in particular not evaporation of the extraction solvent), partially or completely, in particular under vacuum, to more or less remove the extraction solvent and obtain either the dry extract if the solvent is completely removed, or the concentrated extract which is diluted in residual solvent.
  • the oil obtained from achenes of Silybum marianum may advantageously be obtained by extraction from achenes of Silybum marianum (L.) Gaertn. (the achenes can be whole or in pieces), in particular by pressure, advantageously by cold pressing (that is to say without heating), at room temperature).
  • the method according to the invention will comprise the following two successive steps:
  • the method according to the invention will comprise the following successive steps:
  • extraction of an oil from achenes of Silybum marianum (L.) Gaertn. (ii) Extraction of the oil obtained from achenes of Silybum marianum (L.) Gaertn with an extraction solvent, comprising, in particular consisting of a hydrotropic aqueous solution, subcritical water or an organic solvent immiscible with the water. oil obtained from achenes of Silybum marianum (L.) Gaertn. possibly mixed with water,
  • Step (i) will advantageously be carried out by cold pressing the achenes of Silybum marianum (L.) Gaertn., Whole or in pieces.
  • Step (ii) will advantageously be carried out with an extraction solvent as defined above, and in particular chosen from methanol, a methanol / water mixture, ethanol, an ethanol / water mixture, isopropanol, and a mixture isopropanol / water.
  • an extraction solvent as defined above, and in particular chosen from methanol, a methanol / water mixture, ethanol, an ethanol / water mixture, isopropanol, and a mixture isopropanol / water.
  • the extraction solvent may in particular be an organic solvent immiscible with the oil obtained from achenes of Silybum marianum (L.) Gaertn, in particular a C1 to C3 alcohol such as methanol, ethanol or alcohol.
  • 'isopropanol optionally mixed with water, in particular in an organic solvent / water volume ratio of between 80/20 and 100/0, in particular between 85/15 and 95/5, in particular of approximately 90/10 .
  • a preferred extraction solvent is an isopropanol / water mixture in a volume ratio of about 90/10.
  • the extraction step (ii) can be carried out by mixing the oil obtained from achenes of Silybum marianum with the extraction solvent for 1 to 12 h and in particular at a temperature of 15 to 25 ° C, in particular approximately 20 ° C.
  • the amount of extraction solvent used to perform this extraction will advantageously be from 0.5 to 3 g, in particular from 1 to 3 g per 1 g of oil obtained from achenes of Silybum marianum (L.) Gaertn ..
  • This extraction step (ii) makes it possible to obtain at the end an extraction phase of interest and a lipid phase.
  • Step (iii) will advantageously be carried out by separating the extraction phase from the lipid phase.
  • Step (iv) will advantageously be carried out under vacuum.
  • the present invention relates to an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention for its use for promoting hair growth.
  • the invention also relates to an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention for its use in the treatment or prevention of alopecia such as Androgenetic alopecia, reactive alopecia, postmenopausal alopecia or areata alopecia, or to treat dissecting folliculitis.
  • alopecia such as Androgenetic alopecia, reactive alopecia, postmenopausal alopecia or areata alopecia, or to treat dissecting folliculitis.
  • Achenes extract from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention can be used in support of a hair transplant, in particular during micro- transplantation of follicular units.
  • a follicular unit is a group of hairs, naturally joined together in the scalp in small bundles, which can contain one to four hairs.
  • the use of an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention is perfectly suitable, in particular as an accompaniment to a laser hair transplant.
  • Achenes extract from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention can also be used in conjunction with a treatment based on plasma rich in platelets (PRP). It is a concentrate of platelets, and therefore rich in growth factors, which is injected into the scalp.
  • PRP plasma rich in platelets
  • Achenes extract from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention can also be used in conjunction with hair mesotherapy.
  • This is a technique commonly used in the medical and aesthetic world, which consists of injecting different polyvitamins into the dermis of the scalp to nourish the hair follicle in depth, which makes it possible to treat the hair while improving blood circulation to the scalp. Usually two months of treatment are enough to normalize the hair loss and sometimes increase the hair density.
  • the present invention relates to a dermatological or cosmetic composition
  • a dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention, with at least one dermatologically or cosmetically acceptable excipient for its use to promote growth capillary.
  • the invention also relates to a dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn.
  • alopecia such as androgenetic alopecia, reactive alopecia, post-menopausal alopecia or alopecia areata, or else to treat dissecting folliculitis.
  • the dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention, with at least one dermatologically or cosmetically acceptable excipient can be used as an accompaniment to a hair transplant, including a laser hair transplant.
  • the dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention, with at least one dermatologically or cosmetically acceptable excipient can also be used as an accompaniment to treatment with platelet rich plasma (PRP).
  • PRP platelet rich plasma
  • the dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention, with at least one dermatologically or cosmetically acceptable excipient can also be used as an accompaniment to 'capillary mesotherapy.
  • the dermatological or cosmetic composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract according to the invention, with at least one dermatologically or cosmetically acceptable excipient can thus be used beforehand or concomitantly hair transplant or scalp medical treatment such as platelet rich plasma treatment or hair mesotherapy.
  • the extract included in the dermatological or cosmetic composition is as described above.
  • the present invention relates to a method of dermatological treatment of an area of the scalp devoid of hair, comprising the topical application to the area of the scalp devoid of hair of an extract of achenes from Silybum marianum ( L.) Gaertn. comprising less than 0.2%, preferably less than 0.1% by weight of silymarin relative to the weight of the dry extract or of a dermatological composition comprising at least one extract of achenes from Silybum marianum (L.) Gaertn.
  • this method of dermatological treatment according to the invention precedes a hair transplant, in particular a laser transplant.
  • the dermatological treatment method according to the invention is carried out for 1 to 6 weeks, preferably 1 to 4 weeks and more preferably 2 to 4 weeks before a hair transplant or a medical treatment of the scalp such as a treatment with a plasma rich in platelets or a hair mesotherapy.
  • the invention is preferably aimed at an extract and a cosmetic or dermatological composition according to the invention which is provided in its own form and suitable for topical application, in particular to the scalp and / or the hair.
  • the cosmetic or dermatological composition according to the invention can thus be provided in the forms which are usually known for topical administration, that is to say in particular lotions, shampoos, balms, foams, gels, dispersions. , emulsions, sprays, serums, masks or creams, with excipients allowing in particular penetration in order to improve the properties and accessibility of the active principle.
  • composition according to the invention can be provided in the forms which are usually known for topical administration to the hair and the scalp, that is to say in particular a shampoo, a conditioner, a hair cream, a hair lotion, a mask or a spray, in particular without rinsing.
  • the composition according to the invention has a light texture further allowing optimum penetration without greasing the hair and / or the body hair, or the scalp.
  • the composition according to the present invention will comprise, in particular will consist of, an extract according to the invention, isopropanol and PEG.
  • the isopropanol / PEG mass ratio will advantageously be between 1/2 and 2/1, in particular between 1 / 1.5 and 1.5 / 1, in particular will be approximately 1/1.
  • the PEG may in particular have a number-average molecular mass of between 200 and 600 g / mol, in particular between 200 and 500 g / mol, in particular between 200 and 400 g / mol, for example between 250 and 350 g / mol, in particular about 300 g / mol. It may thus be in particular PEG 300.
  • the composition according to the invention is characterized in that it is provided in a form suitable for oral administration.
  • composition according to the invention may then be in the forms which are usually known for oral administration, that is to say in particular tablets, gelatin capsules, powders, granules and oral solutions or suspensions.
  • the main active ingredient can be mixed with a cosmetic or dermatological vehicle such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic. , silica or the like.
  • the tablets can be coated with sucrose or other suitable materials or they can be treated so that they have a prolonged or delayed activity and that they continuously release a predetermined amount of active.
  • a capsule preparation can be obtained by mixing the active ingredient with a diluent and pouring the resulting mixture into soft or hard capsules.
  • the composition according to the present invention comprises 0.01 to 15% by weight, preferably 0.1 to 10% by weight, of an extract according to the invention relative to the total volume of the composition.
  • extract M Methanolic (extract M) and ethanolic (extract E) extracts were obtained in a similar manner by replacing the isopropanol / water mixture (90/10 v / v) respectively with methanol and an ethanol / water mixture (90/10 v / v).
  • the oil obtained from achenes of Silybum marianum is extracted respectively with 3 volumes of methanol and 3 volumes of the ethanol / water mixture (90/10 v / v) for 1 volume of oil for 2 hours at 20 ° C.
  • Protocol 1 evaluation of the silymarin content by UPLC
  • Silymarin control prepare a 5 mg solution of silymarin in 10 ml of a methanol / water (60:40) (v / v) mixture.
  • Protocol 2 Evaluation of the linoleic acid content by UPLC Preparation of the sample and the control:
  • Control Linoleic acid prepare a 10 mg solution of linoleic acid in 10 ml of a methanol / dichloromethane (1: 1) (v / v) mixture.
  • Injection volume 1 pL.
  • Protocol 3 Evaluation of the fatty acid content by GC-MS Preparation of the sample: Heat the dry extract to be analyzed at 35 ° C while stirring until a clear homogeneous liquid is obtained.
  • the silymarin content of extracts I was determined by LIPLC after calibration with control solutions of commercial silymarin (Sigma Aldrich).
  • Extract I contains 0.06% by mass of silymarin.
  • extract M methanolic
  • extract E ethanolic 90
  • extract I isopropanolic 90
  • the various analyzes carried out by UPLC and GC-MS made it possible to highlight the following characteristics:
  • the isopropanolic extract 90 of achenes according to the invention contains virtually no silymarin, particularly polar flavonolignans.
  • Example 2 Quantification of the Keratin 75 protein in the forehead follicles of human subjects
  • the purpose of this example is to evaluate the effects of an extract of achenes from Silybum marianum (L.) Gaertn. comprising less than 0.2% by weight of silymarin on the expression of the protein Keratin 75 in humans. Indeed, such pharmacological activity is of interest in the field of treatment and / or prevention of hair loss, in particular by promoting their growth.
  • a topical preparation of extract I prepared in Example 1 was formulated at 1.75% or 7.0% (w / v) of the dry extract, in an isopropanol / PEG 300 (1: 1) mixture. ) (w / w), then put in a spray for application twice a day for the duration of treatment.
  • the biopsies are detached from the glass slide in distilled water for 30 minutes at room temperature, are cut into small parts and then homogenized in a 2 mM Tris-HCl extraction buffer, pH 6.8, 3% SDS, lOmM sodium pyrophosphate, 5mM EDTA, and 2mM sodium vanadate. The samples are heated to 50 ° C for
  • the extracts are centrifuged at 10,000 revolutions / min for 10 minutes.
  • the determination of the proteins in the supernatants is carried out by the method according to Bradford (Anal Biochem 72: 248-254, 1976) using the Bio-Rad reagent (Cressier, Switzerland).
  • the sebocyte cultures are washed with PB S buffer then the cells are lysed in a specific buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, ImM EDTA, 1% Triton TM X-100).
  • the suspensions are passed through a sonicator and then analyzed by the Bradford method.
  • Protein samples are analyzed by Western Blot using a standard procedure and the following antibody: polyclonal rabbit anti-human IgG K75, dilution 1: 5000 (Fisher Scientific, Reinach, Switzerland).
  • Proteomic analysis was performed by electrophoresis (SDS-PAGE), followed by Coomassie staining. The colored protein bands are harvested and analyzed on the University of Geneva's proteomics platform.
  • the level of expression of the K75 protein (densitometric unit of western blot bands) in the hair follicles of the forehead of human subjects is shown in the table
  • the inventors clearly demonstrate that the treatment with an extract according to the invention induces a statistically significant increase (p ⁇ 0.001) in the expression of the K75 protein. It is interesting to note that this increase is observed in all patients regardless of the concentration tested or the duration of treatment carried out. Indeed, after 4 weeks of treatment, the increase in the expression of the K75 protein already seems very marked.
  • Example 3 quantification of the Keratin 75 protein in the scalp of a patient with alopecia areata
  • the inventors thus demonstrate that a treatment comprising an extract according to the invention makes it possible to significantly increase the level of expression of K75 in a patient suffering from alopecia areata. It is interesting to note that at the end of the treatment, a regrowth capillary could be observed.
  • Example 4 quantification of the Keratin 75 protein at the level of the scalp on patches of alopecia areata and hair regrowth
  • an extract according to the invention to the scalp therefore made it possible to create conditions favorable to hair regrowth.
  • the inventors therefore put clearly evident that such an extract would be useful to apply in prevention of a hair transplant or a medical treatment such as PRP or mesotherapy.
  • Example 5 specific effect of an extract of achenes from Silybum marianum on the phosphorylation of EGFR and PDGFRB receptors in cells of the dermal papilla
  • the objective of this study is to show that an extract of achenes of Silybum marianum tested at 30 pg / mL specifically induces the tyrosine phosphorylation of receptors with tyrosine kinase (phospho-RTK) activity and of kinases of different pathways. signaling (phospho-kinases) unlike Silymarin (Sigma) tested at 0.06 pg / mL.
  • the control was treated with dimethylsulfoxide (DMSO), used as a solvent for Silybum marianum extract and Silymarin.
  • DMSO dimethylsulfoxide
  • the chemiluminescence signals were finally detected using a densitometer (ChemiDoc, Biorad) and quantified with the Image J 1.52 software using the Microarray profile plugin. Analysis of the data made it possible to determine the average pixel intensity for each experimental condition and to measure a ratio relative to the DMSO control. The tests were finally carried out on 2 independent donors of dermal papilla cells and carried out in duplicate. The results of the phosphoreceptors are shown in Table 7 below. [Table 7]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
EP20754703.5A 2019-08-06 2020-08-06 Extrakt von silybum marianum (l.) gaertn. akenes zur förderung des haarwuchses Pending EP4009997A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1909012A FR3099699A1 (fr) 2019-08-06 2019-08-06 Extrait d’akènes de Silybum marianum (L.) Gaertn. pour promouvoir la croissance capillaire
PCT/EP2020/072146 WO2021023820A1 (fr) 2019-08-06 2020-08-06 Extrait d'akènes de silybum marianum (l.) gaertn. pour promouvoir la croissance capillaire

Publications (1)

Publication Number Publication Date
EP4009997A1 true EP4009997A1 (de) 2022-06-15

Family

ID=69743282

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20754703.5A Pending EP4009997A1 (de) 2019-08-06 2020-08-06 Extrakt von silybum marianum (l.) gaertn. akenes zur förderung des haarwuchses

Country Status (7)

Country Link
US (1) US20220331387A1 (de)
EP (1) EP4009997A1 (de)
CN (1) CN114206363B (de)
BR (1) BR112022001032A2 (de)
FR (1) FR3099699A1 (de)
MX (1) MX2022001639A (de)
WO (1) WO2021023820A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3113585A1 (fr) * 2020-08-31 2022-03-04 Pierre Fabre Dermo-Cosmetique Huile de Silybum marianum (L.) Gaertn. dans le renforcement de la fonction barrière de la peau

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678929A1 (fr) 1991-07-11 1993-01-15 Oreal Compositions pour freiner la chute des cheveux et pour induire et stimuler leur croissance a base de derives de 2,4-diamino pyrimidine 3-oxyde, nouveaux derives 2,4-diamino pyrimidine 3-oxyde.
DE4323614A1 (de) * 1993-07-12 1995-01-19 Edelgard Schreiner Mittel zur Stimulierung des Wachstums und der Regenerierung des Haares
WO1998033497A1 (en) 1997-02-04 1998-08-06 Johnstone Murray A Method of enhancing hair growth
FR2809008B1 (fr) * 2000-05-19 2006-07-28 Sarl I De Zica Composition cosmetique renfermant des ceramides associes a de la silymarine
DE102009045981A1 (de) * 2009-10-26 2010-08-05 Henkel Ag & Co. Kgaa Antifalten-Kosmetikum mit Strandkamillenextrakt
FR3053253B1 (fr) 2016-07-01 2020-01-17 Pierre Fabre Dermo-Cosmetique Nouvel extrait d'akenes de silybum marianum et ses utilisations en dermatologie et dermo-cosmetique
FR3075037B1 (fr) * 2017-12-20 2020-07-17 Pierre Fabre Dermo-Cosmetique Association d'un retinoide et d'un extrait de silybum marianum (l.) gaertn

Also Published As

Publication number Publication date
BR112022001032A2 (pt) 2022-06-07
CN114206363A (zh) 2022-03-18
WO2021023820A1 (fr) 2021-02-11
FR3099699A1 (fr) 2021-02-12
MX2022001639A (es) 2022-05-11
CN114206363B (zh) 2023-03-21
US20220331387A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
FR2975495A1 (fr) Methode de criblage de principes actifs favorisant la deglycation des ages
EP2099422B1 (de) Orale verwendung von petroselinsäure zur stärkung der haare
EP3203981B1 (de) Deglykierungaktivität einer kombination von einem salvia miltiorrhiza-extrakt und niacin und/oder niacinamide
FR2755367A1 (fr) Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
EP4009997A1 (de) Extrakt von silybum marianum (l.) gaertn. akenes zur förderung des haarwuchses
CA3119556A1 (fr) Extrait de garcinia mangostana pour promouvoir la croissance capillaire
FR3013985A1 (fr) Compositions hydratantes comprenant au moins un extrait de caesalpinia spinosa, avec au moins de la vaseline et de la glycerine
EP3600369A1 (de) Verwendung eines copaifera-extraktes zur bekämpfung von alopecia und seborrhoea
EP3040105B1 (de) Kosmetische anwendung eines hagebuttenextrakts als mittel gegen seborrhö
EP3829626B1 (de) Lespedeza-capitata-extrakt zur verwendung auf dem gebiet der haarpflege
EP2994091B1 (de) Kombination von petroselinsäure und zink zur oralen verabreichung zwecks alterungssteuerung der haare
FR2784027A1 (fr) Utilisation d'un extrait de boldo dans un produit cosmetique ou dermatologique et produit comportant un tel extrait
FR3061015B1 (fr) Utilisation cosmetique d'un extrait de corchorus olitorius
FR2834639A1 (fr) Composition comprenant en association au moins un flavonoide et au moins une huile vegetale, son utilisation comme agent dermatologique ou dermatocosmetique
EP3787592B1 (de) Kombination von extrakten von chinarinde und leontopodium alpinum und des mangansalzes von l-pyrrolidoncarbonsäure zur behandlung von alopezie
EP1348421A2 (de) Verfahren zur Verdichtung und Formung von menschlichen Keratinfasern unter Verwendung eines bestimmten Katalysatorsystems
FR2909870A1 (fr) Utilisation topique d'au moins un acide gras mono-insature pour ameliorer la chevelure
WO2004089390A2 (fr) Utilisation du quinquina pour la preparation d’un medicament stimulant l’angiogenese
EP2994099B1 (de) Kombination aus petroselinsäure und taurin zur oralen verabreichung zwecks bekämpfung der alterung der haare
FR3101545A1 (fr) Utilisation cosmétique ou nutraceutique d’un extrait deTerminalia catappa
EP1082125A1 (de) Pharmazeutische oder kosmetische zusammensetzung und verfahren zur kosmetischen behandlung von angiogenischen erkrankungen
FR3099702A1 (fr) Nouvelle utilisation cosmétique d’un extrait d’Epilobium angustifolium
FR2939038A1 (fr) Association d'acide glutamique, de threonine, d'asparagine et d'alanine pour lutter contre l'alopecie chez l'homme
FR2847805A1 (fr) Procede de densification des fibres keratiniques humaines utilisant un systeme catalytique particulier

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PIERRE FABRE DERMO-COSMETIQUE

17Q First examination report despatched

Effective date: 20231102